Delving into the Latest Updates on Sichuan Guowei Pharmaceutical Co., Ltd. with Synapse

Overview

Tags

Digestive System Disorders

Other Diseases

Small molecule drug

Disease domain score

A glimpse into the focused therapeutic areas

No Data

Technology Platform

Most used technologies in drug development

Targets

Most frequently developed targets

Top 5 Drug Type	Count

Small molecule drug	2

Top 5 Target	Count

PKC(Protein kinase C)	1
5-HT2C receptor x MTNR1A x MTNR1B	1

主要目的：以四川国为制药有限公司生产的艾拉莫德片（25mg/片）为受试制剂，以海南先声药业有限公司生产的艾拉莫德片（25mg/片，艾得辛）为参比制剂，考察两制剂的生物等效性。次要目的：观察受试制剂和参比制剂在健康受试者中的安全性。

[Translation]

Main purpose: Using Iguratimod tablets (25 mg/tablet) produced by Sichuan Guowei Pharmaceutical Co., Ltd. as the test preparation and Iguratimod tablets (25 mg/tablet, Edexin) produced by Hainan Xiansheng Pharmaceutical Co., Ltd. as the reference preparation, the bioequivalence of the two preparations was investigated. Secondary purpose: Observe the safety of the test preparation and the reference preparation in healthy subjects.

Start Date29 Jan 2024

Sponsor / Collaborator

Sichuan Guowei Pharmaceutical Co., Ltd.

CTR20232695 / CompletedNot Applicable

乌帕替尼缓释片的单中心、开放、随机、单剂量给药临床试验

[Translation] A single-center, open-label, randomized, single-dose clinical trial of upadacitinib extended-release tablets

以四川国为制药有限公司生产的乌帕替尼缓释片（15mg/片）为受试制剂，以 AbbVie Ireland NLB.V.公司生产的乌帕替尼缓释片（15mg/片）为参比制剂（商品名：瑞福®），考察两制剂的生物等效性。

[Translation]

Upadacitinib sustained-release tablets (15 mg/tablet) produced by Sichuan Guowei Pharmaceutical Co., Ltd. were used as the test preparation, and upadacitinib sustained-release tablets (15 mg/tablet) produced by AbbVie Ireland NLB.V. were used as the reference preparation (trade name: Ruifu®) to investigate the bioequivalence of the two preparations.

Start Date27 Aug 2023

Sponsor / Collaborator

Sichuan Guowei Pharmaceutical Co., Ltd.

CTR20232002 / CompletedNot Applicable

罗沙司他胶囊的单中心、开放、随机、单剂量、两周期、双交叉设计试验

[Translation] A single-center, open-label, randomized, single-dose, two-period, double-crossover design trial of rosuvastatin capsules

主要目的：以四川国为制药有限公司生产的罗沙司他胶囊（50mg/粒）为受试制剂，以珐博进（中国）医药技术开发有限公司生产的罗沙司他胶囊（50mg/粒）为参比制剂，考察两制剂的生物等效性。次要目的：考察受试制剂和参比制剂在健康受试者中的安全性。

[Translation]

Main purpose: Using rosuvastatin capsules (50 mg/capsule) produced by Sichuan Guowei Pharmaceutical Co., Ltd. as the test preparation and rosuvastatin capsules (50 mg/capsule) produced by FibroGen (China) Pharmaceutical Technology Development Co., Ltd. as the reference preparation, the bioequivalence of the two preparations was investigated. Secondary purpose: Investigate the safety of the test preparation and the reference preparation in healthy subjects.

Start Date20 Jul 2023

Sponsor / Collaborator

Sichuan Guowei Pharmaceutical Co., Ltd.

100 Clinical Results associated with Sichuan Guowei Pharmaceutical Co., Ltd.

Login to view more data

0 Patents (Medical) associated with Sichuan Guowei Pharmaceutical Co., Ltd.

Login to view more data

100 Deals associated with Sichuan Guowei Pharmaceutical Co., Ltd.

Login to view more data

100 Translational Medicine associated with Sichuan Guowei Pharmaceutical Co., Ltd.

Login to view more data

Corporation Tree

Boost your research with our corporation tree data.

login

or

view full example data

Boost your research with our corporation tree data.

Pipeline

Pipeline Snapshot as of 15 Nov 2024

The statistics for drugs in the Pipeline is the current organization and its subsidiaries are counted as organizations,Early Phase 1 is incorporated into Phase 1, Phase 1/2 is incorporated into phase 2, and phase 2/3 is incorporated into phase 3

Phase 1 Clinical

2

Login to view more data